Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.
Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.
All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi's Dupixent granted Priority Review by FDA for potential COPD indication based on positive Phase 3 trial results, aiming to be the only biologic therapy for COPD and the first new treatment approach in over a decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA Priority Review for linvoseltamab to treat relapsed/refractory multiple myeloma. The BLA is supported by Phase 1/2 trial data, with a target action date of August 22, 2024. Linvoseltamab aims to activate T cells for cancer-cell killing in MM patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
News
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi receive approval in Japan for Dupixent to treat chronic spontaneous urticaria, expanding its indications globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) will participate in several upcoming healthcare conferences, with webcasts available for investors and media. The sessions will be accessible from the company's website, with replays and transcripts archived for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported a 1% increase in fourth quarter 2023 revenues to $3.43 billion, with a 14% increase excluding Ronapreve. Full year 2023 revenues increased 8% to $13.12 billion, with a 12% increase excluding Ronapreve. The company's Dupixent global net sales increased significantly, with a 31% increase in the fourth quarter and a 33% increase for the full year. The GAAP diluted EPS was $10.19, and non-GAAP diluted EPS was $11.86 in the fourth quarter. The company's business update highlighted significant pipeline progress and upcoming milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
News
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. announces the acceptance for review of the Marketing Authorization Application for linvoseltamab by the European Medicines Agency. The application is for the treatment of adult patients with relapsed/refractory multiple myeloma who have progressed after at least three prior therapies. The drug is an investigational bispecific antibody designed to facilitate T-cell activation and cancer-cell killing. The MAA is supported by data from a Phase 1/2 pivotal trial and a Biologics License Application was also submitted to the FDA. Multiple trials are planned or underway for linvoseltamab in different stages of multiple myeloma. MM is characterized by the proliferation of cancerous plasma cells and is not curable despite treatment advances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies. The company will pay an upfront payment of $5 million and a single milestone payment from Regeneron to 2seventy bio for the first major market approval of the first approved product. Regeneron will also pay 2seventy bio a low single-digit percent royalty on revenues generated by the products. The transaction is expected to close in the first half of 2024 subject to certain closing conditions including SEC-filings required by 2seventy bio and landlord consent of the sublease agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. and Sanofi have announced the FDA approval of Dupixent for the treatment of pediatric patients aged 1 to 11 years with eosinophilic esophagitis (EoE). The approval expands the initial FDA approval for EoE in patients aged 12 years and older. The Phase 3 EoE KIDS trial showed that a greater proportion of children taking Dupixent achieved histological remission compared to placebo. The safety profile of Dupixent in children was generally similar to that observed in adult and pediatric patients aged 12 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. and Society for Science announce the top 40 finalists in the 2024 Regeneron Science Talent Search, showcasing exceptional young leaders in science and math. The finalists' research projects cover a wide range of topics, from brain disorders and suicide risk to local environment studies. The finalists will compete for more than $1.8 million in awards, with a top prize of $250,000. The competition received the largest pool of applicants since the 1960s, highlighting the increasing importance of scientific exploration and outreach programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi announced that the FDA has updated the label for Dupixent in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with uncontrolled moderate-to-severe hand and/or foot involvement. The Phase 3 trial showed significant improvement in skin clarity and itch reduction for patients treated with Dupixent compared to placebo. The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial, with patients treated with Dupixent experiencing a 40% achievement of clear or almost clear skin on hands and feet compared to 17% with placebo, as well as a 52% reduction in itch compared to 14% with placebo. The safety profile of Dupixent remains consistent with known data, with common adverse events including injection site reactions, conjunctivitis, and others.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
Regeneron Pharmaceuticals
Nasdaq:REGN
REGN Rankings
REGN Stock Data
60.05B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
United States
TARRYTOWN